EP Patent

EP3106457A1 — A novel synthetic pathway towards apremilast

Assigned to Lek Pharmaceuticals dd · Expires 2016-12-21 · 9y expired

What this patent protects

The present invention relates to a process for providing a chiral β-hydroxysulfone compound, an intermediate useful in the synthesis of the isoindoline-based compound apremilast.

USPTO Abstract

The present invention relates to a process for providing a chiral β-hydroxysulfone compound, an intermediate useful in the synthesis of the isoindoline-based compound apremilast.

Drugs covered by this patent

Patent Metadata

Patent number
EP3106457A1
Jurisdiction
EP
Classification
—
Expires
2016-12-21
Drug substance claim
No
Drug product claim
No
Assignee
Lek Pharmaceuticals dd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.